Kreatsoulas Daniel C, Kim Joanne, Damante Mark, Orr Anna, Wang Joshua, Vignolles-Jeong Joshua, Gruber Maxwell, Shah Varun, Musgrave Nicholas, Lonser Russell, Prevedello Daniel, Elder J Bradley, Hardesty Douglas A
Department of Neurological Surgery, The Ohio State University Wexner Medical Center, N1019 Doan Hall, 410 West 10th Avenue, Columbus, OH, 43210, USA.
Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
J Neurooncol. 2025 Sep;174(3):799-808. doi: 10.1007/s11060-025-05109-7. Epub 2025 Jun 11.
Brain metastasis patients require granular surgical risk evaluation. The authors aimed to improve prognostication for brain metastasis patients by creating the Metastatic Brain Lesion Score (MBLS).
This is a retrospective cohort study of patients undergoing craniotomy for brain metastasis between Jan 1, 2014 and Sept 30, 2021 at a large tertiary referral center. Patients were excluded if they had craniotomy for non-metastatic lesions, radiation necrosis, or skull metastases only. The primary outcome was to define factors that predicted mortality at 90 days. Secondary measures were mFI-11 and RPA classifications. Multivariable logistic regression analyses were conducted to identify the clinically and statistically relevant predictors for the predicted mortality at 90 days with the creation cohort (n = 548). The metric developed was validated with the new data (validation cohort, n = 318), and was compared its prediction performance with secondary measures.
866 consecutive patients (n = 548 creation cohort, n = 318 validation cohort) were reviewed and analyzed. Score factors included in the MBLS were: age > 65 (OR 1.97 (95%CI 1.19-3.02)), presence of supra- and infratentorial metastases (OR 1.696 (1.04-2.78)); hemorrhagic metastasis (OR 1.699 (1.09-2.64)); chronic opiate use (OR 2.34 (1.43-3.84)); poor functional status (OR 1.90 (1.22-2.97)); and presence of deep brain/brainstem lesions (OR 2.01 (1.07-3.78)). 61/164 (37.2%) creation cohort patients and 51/116 (43.9%) validation cohort patients with MBLS score ≥ 3 were deceased at 3 months. High-risk patients in the creation cohort were significantly more likely to be deceased 3 months postoperatively (OR 3.699 (95%CI 2.41-5.682), P < 0.001). In the validation cohort, MBLS was highly predictive (OR 5.311 (95%CI 3.06-9.22), P < 0.001) with a c-statistic of 0.696.
The MBLS provides "high-risk" surgical categorization for brain metastasis patients. By using preoperative characteristics obtainable from imaging and chart review, it can be utilized in preoperative discussions, giving a clearer view of potential postoperative course and outcome.
脑转移瘤患者需要进行细致的手术风险评估。作者旨在通过创建脑转移瘤病变评分(MBLS)来改善脑转移瘤患者的预后预测。
这是一项对2014年1月1日至2021年9月30日在一家大型三级转诊中心接受开颅手术治疗脑转移瘤的患者进行的回顾性队列研究。如果患者因非转移性病变、放射性坏死或仅颅骨转移而接受开颅手术,则将其排除。主要结局是确定预测90天死亡率的因素。次要指标是改良功能独立性量表-11(mFI-11)和递归分区分析(RPA)分类。进行多变量逻辑回归分析,以确定创建队列(n = 548)中预测90天死亡率的临床和统计学相关预测因素。所开发的指标在新数据(验证队列,n = 318)中进行验证,并将其预测性能与次要指标进行比较。
对866例连续患者(创建队列n = 548,验证队列n = 318)进行了回顾和分析。MBLS中包含的评分因素为:年龄>65岁(比值比[OR]1.97[95%置信区间(CI)1.19 - 3.02])、幕上和幕下转移瘤的存在(OR 1.696[1.04 - 2.78]);出血性转移(OR 1.699[1.09 - 2.64]);长期使用阿片类药物(OR 2.34[1.43 - 3.84]);功能状态差(OR 1.90[1.22 - 2.97]);以及深部脑/脑干病变的存在(OR 2.01[1.07 - 3.78])。创建队列中MBLS评分≥3的61/164(37.2%)患者和验证队列中51/116(43.9%)患者在3个月时死亡。创建队列中的高危患者术后3个月死亡的可能性显著更高(OR 3.699[95%CI 2.41 - 5.682],P < 0.001)。在验证队列中,MBLS具有高度预测性(OR 5.311[95%CI 3.06 - 9.22],P < 0.001),c统计量为0.696。
MBLS为脑转移瘤患者提供了“高危”手术分类。通过使用可从影像学和病历审查中获得的术前特征,它可用于术前讨论,更清楚地了解潜在的术后病程和结局。